Last reviewed · How we verify
Boceprevir (BOC)
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication. Used for Chronic hepatitis C virus (HCV) infection, genotype 1, in combination with peginterferon alfa and ribavirin.
At a glance
| Generic name | Boceprevir (BOC) |
|---|---|
| Also known as | SCH 503034, Victrelis |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | HCV NS3 protease inhibitor |
| Target | HCV NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | Phase 3 |
Mechanism of action
Boceprevir directly inhibits the HCV NS3/4A serine protease, an enzyme essential for cleaving viral polyproteins into functional proteins required for viral replication. By blocking this protease, the drug prevents the maturation of viral proteins and halts HCV replication. It is used in combination with interferon-alpha and ribavirin for treatment of chronic hepatitis C.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1, in combination with peginterferon alfa and ribavirin
Common side effects
- Anemia
- Dysgeusia (taste perversion)
- Nausea
- Fatigue
- Neutropenia
Key clinical trials
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection (PHASE3)
- Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PHASE3)
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) (PHASE3)
- Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO) (PHASE1)
- Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) (PHASE3)
- Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) (PHASE3)
- Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |